OBJECTIVES: To determine (1) if radiotherapy (RT) improves survival or neurologic function in elderly patients with malignant supratentorial glioma (MSG) and (2) which prognostic factors predict survival. BACKGROUND: The prevalence of MSG is increasing because both the number of elderly patients and the age-adjusted incidence are increasing. Because age is a powerful negative prognostic factor in MSG, it is not clear if RT is useful in the elderly. DESIGN/ METHODS: We retrospectively studied 103 patients from the Southern Alberta Cancer Registry diagnosed January 1, 1978, to December 31, 1993, aged 70 yrs, with MSG in whom sufficient clinical and follow-up information was available. Multiple treatment and patient factors were compared with survival and neurologic function score. Diagnosis was confirmed in 15 (14.6%) by biopsy, in 66 (64.1%) by resection, and in 22 (21.4%) by clinical course and typical radiographic appearance only. RESULTS: All patients died and median survival was 3.9 months. Better neurologic function at diagnosis and administration of RT were independently associated with significantly longer survivals (p = 0.001 and < 0.001; log rank test). However, RT was only associated with longer survival in patients aged less than 80 years. Neurologic status only rarely improved following RT. CONCLUSIONS: The prognosis for elderly patients with MSG is poor. RT is unlikely to benefit patients who are aged 80 years or older. RT has a short-lived benefit for patients who are functionally disabled.
OBJECTIVES: To determine (1) if radiotherapy (RT) improves survival or neurologic function in elderly patients with malignant supratentorial glioma (MSG) and (2) which prognostic factors predict survival. BACKGROUND: The prevalence of MSG is increasing because both the number of elderly patients and the age-adjusted incidence are increasing. Because age is a powerful negative prognostic factor in MSG, it is not clear if RT is useful in the elderly. DESIGN/ METHODS: We retrospectively studied 103 patients from the Southern Alberta Cancer Registry diagnosed January 1, 1978, to December 31, 1993, aged 70 yrs, with MSG in whom sufficient clinical and follow-up information was available. Multiple treatment and patient factors were compared with survival and neurologic function score. Diagnosis was confirmed in 15 (14.6%) by biopsy, in 66 (64.1%) by resection, and in 22 (21.4%) by clinical course and typical radiographic appearance only. RESULTS: All patients died and median survival was 3.9 months. Better neurologic function at diagnosis and administration of RT were independently associated with significantly longer survivals (p = 0.001 and < 0.001; log rank test). However, RT was only associated with longer survival in patients aged less than 80 years. Neurologic status only rarely improved following RT. CONCLUSIONS: The prognosis for elderly patients with MSG is poor. RT is unlikely to benefit patients who are aged 80 years or older. RT has a short-lived benefit for patients who are functionally disabled.
Authors: Jill S Barnholtz-Sloan; John L Maldonado; Vonetta L Williams; William T Curry; Elizabeth A Rodkey; Frederick G Barker; Andrew E Sloan Journal: J Neurooncol Date: 2007-05-26 Impact factor: 4.130
Authors: L Fariselli; V Pinzi; I Milanesi; A Silvani; M Marchetti; M Farinotti; A Salmaggi Journal: Strahlenther Onkol Date: 2013-04-28 Impact factor: 3.621
Authors: J Y Pierga; K Hoang-Xuan; L Feuvret; J M Simon; P Cornu; F Baillet; J J Mazeron; J Y Delattre Journal: J Neurooncol Date: 1999-06 Impact factor: 4.130
Authors: Angelique E Sijben; John B McIntyre; Gloria B Roldán; Jacob C Easaw; Elizabeth Yan; Peter A Forsyth; Ian F Parney; Anthony M Magliocco; Hans Bernsen; J Gregory Cairncross Journal: J Neurooncol Date: 2008-04-09 Impact factor: 4.130
Authors: Giuseppe Minniti; V De Sanctis; R Muni; D Rasio; G Lanzetta; A Bozzao; M F Osti; M Salvati; M Valeriani; G P Cantore; R Maurizi Enrici Journal: J Neurooncol Date: 2008-08-29 Impact factor: 4.130
Authors: G Minniti; V De Sanctis; R Muni; F Filippone; A Bozzao; M Valeriani; M F Osti; U De Paula; G Lanzetta; V Tombolini; R Maurizi Enrici Journal: J Neurooncol Date: 2008-02-05 Impact factor: 4.130